Agarwal, N., Azad, A., Carles, J., Fay, A. P., Matsubara, N., Szczylik, C., Giorgi, U. D., Joung, J. Y., Fong, P. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C. J., Zschaebitz, S., Oldenburg, J., Lin, X., Healy, C., Kalac, M., Kennedy, D. A., Fizazi, K. (2025). Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.lba18